Streetbeat News

Products Services

BTAI

The Centers for Medicare & Medicaid Services has issued a permanent and product-specific J-code for BioXcel Therapeutics' Igalmi Sublingual Film, which is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The IGALMI J-Code J1105 will become effective from January 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 11:21 am

TNXP

Tonix Pharmaceuticals has announced new data involving TNX-1500 in heart xenotransplantation in animal models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 11:18 am

VYNE

VYNE Therapeutics Inc. has announced positive data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. The trial assessed the safety, tolerability and pharmacokinetics of VYN201 in 29 patients across three dose cohorts. The efficacy of VYN201 was also evaluated, including its ability to arrest the progression of skin depigmentation and support skin repigmentation in patients with active disease.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 11:07 am

CSIQ

Canadian Solar is constructing a solar photovoltaic cell manufacturing plant in Jeffersonville, Indiana. The facility will have an annual output of 5 GW, equivalent to around 20,000 high-power modules daily.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 11:05 am

JKS

JinkoSolar has announced that its N-type monocrystalline silicon solar cell has set a new record with a maximum conversion efficiency of 26.89% for its 182mm and above large-size variant.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 11:04 am

DCPH

Deciphera Pharmaceuticals' Phase 3 study of Vimseltinib for Tenosynovial Giant Cell Tumor met its primary endpoint with an objective response rate at week 25 of 40% compared to 0% for placebo.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 11:03 am

BMY

The European Medicines Agency (EMA) has validated Bristol Myers Squibb's application for Opdivo (nivolumab) in combination with cisplatin-based chemotherapy for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 11:00 am

MX

Magnachip Semiconductor has announced the release of its 6th-generation 600V Super Junction Metal Oxide Semiconductor Field Effect Transistor (MOSFET) enhanced with microfabrication technology.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 10:58 am

JKS

JinkoSolar Holding Co. anticipates its Q4 module shipments to reach 23 GW and aims to surpass its FY23 outlook of 70.0 GW - 75.0 GW. The company also expects its annual production capacity for mono wafer, solar cell, and solar module to reach 85.0 GW, 90.0 GW, and 110.0 GW, respectively, by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 10:58 am

MNKD

MannKind Corporation has announced a new US patent for its Clofazimine Inhalation Suspension (MNKD-101), which is under development for Nontuberculous Mycobacterial Lung Disease. The patent will expire on June 8, 2039.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 10:21 am